Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

NCT01168050 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Malignant Skin Melanoma T0
Stage III Melanoma
Stage IV Melanoma
Amplification

Interventions

DRUG: Nilotinib

Sponsor

Assistance Publique - Hôpitaux de Paris